Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension.

PH (pulmonary hypertension) often complicates the disease course of patients with COPD (chronic obstructive pulmonary disease) and is an indication of a worse prognosis. In the present study, we assessed whether pravastatin administration was effective in improving PH and exercise capacity in COPD patients with PH, and whether the pulmonary protection was mediated by inhibiting ET-1 (endothelin-1) production. In a double-blind parallel design, 53 COPD patients with PH were randomly assigned to receive either placebo or pravastatin (40 mg/day) over a period of 6 months at a medical centre. Baseline characteristics were similar in both groups. The exercise time remained stable throughout the study in the placebo group. After 6 months, the exercise time significantly increased 52% from 660+/-352 to 1006+/-316 s (P<0.0001) in pravastatin-treated patients. With pravastatin, echocardiographically derived systolic PAP (pulmonary artery pressure) decreased significantly from 47+/-8 to 40+/-6 mmHg. There was significant improvement in the Borg dyspnoea score after administering pravastatin. Despite unchanged plasma ET-1 levels throughout the study, urinary excretion of the peptide was decreased and significantly correlated with an improvement in exercise time in pravastatin-treated patients (r=-0.47, P=0.01). In conclusion, pravastatin significantly improved exercise tolerance, and decreased PH and dyspnoea during exercise in COPD patients with PH, probably by inhibiting ET-1 synthesis.

[1]  D. Huo,et al.  Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  L. Rochette,et al.  The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  Nan-Hung Pan,et al.  Association of gliclazide and left ventricular mass in type 2 diabetic patients. , 2006, Diabetes research and clinical practice.

[4]  T. Shim,et al.  Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. , 2005, American journal of respiratory and critical care medicine.

[5]  Morton F Arnsdorf,et al.  The prognostic value of a nomogram for exercise capacity in women. , 2005, The New England journal of medicine.

[6]  A. Churg,et al.  Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment , 2005, Thorax.

[7]  M. Rubenfire,et al.  The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. , 2005, Vascular pharmacology.

[8]  A. Sala,et al.  Lipid peroxidation and 5-lipoxygenase activity in chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.

[9]  A. Torbicki,et al.  Diagnosis and differential assessment of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[10]  J. Saxton,et al.  Treadmill versus shuttle walk tests of walking ability in intermittent claudication. , 2004, Medicine and science in sports and exercise.

[11]  T. Chou,et al.  Effects of pravastatin on cardiomyocyte hypertrophy and ventricular vulnerability in normolipidemic rats after myocardial infarction. , 2003, Journal of molecular and cellular cardiology.

[12]  D. Sin,et al.  Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. , 2003, Circulation.

[13]  T. Chou,et al.  Association of Pravastatin and Left Ventricular Mass in Hypercholesterolemic Patients: Role of 8-Iso-Prostaglandin F2&agr; Formation , 2002, Journal of cardiovascular pharmacology.

[14]  N. Morrell,et al.  Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. , 2002, Progress in cardiovascular diseases.

[15]  Shing M. Lee,et al.  Hemodynamic characterization of patients with severe emphysema. , 2002, American journal of respiratory and critical care medicine.

[16]  S. Su,et al.  Effect of Pravastatin on Proteinuria in Patients With Well-Controlled Hypertension , 2002, Hypertension.

[17]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[18]  A. Evans,et al.  Inhibition of sustained hypoxic vasoconstriction by Y‐27632 in isolated intrapulmonary arteries and perfused lung of the rat , 2000, British journal of pharmacology.

[19]  K. Morris,et al.  Mechanism of hypoxic pulmonary vasoconstriction involves ET(A) receptor-mediated inhibition of K(ATP) channel. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[20]  R. Pistelli,et al.  Electrocardiographic signs of chronic cor pulmonale: A negative prognostic finding in chronic obstructive pulmonary disease. , 1999, Circulation.

[21]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[22]  J. Hoidal,et al.  ET-1 modulates KCa-channel activity and arterial tension in normoxic and hypoxic human pulmonary vasculature. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[23]  Y. T. Lee,et al.  Effects of dobutamine on aortic valve indexes in asymptomatic patients with bileaflet mechanical prostheses in the aortic valve position. , 1997, The American journal of cardiology.

[24]  L. Hands,et al.  A comparative study of treadmill tests and heel raising exercise for peripheral arterial disease. , 1997, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[25]  D. Kohan.  Endothelins in the normal and diseased kidney. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  A. Carayon,et al.  Endothelin-1 in the lungs of patients with pulmonary hypertension. , 1997, Cardiovascular research.

[27]  E. Weitzenblum,et al.  Medical treatment of pulmonary hypertension in chronic lung disease. , 1994, The European respiratory journal.

[28]  M. Alifano,et al.  Increased 24-hour endothelin-1 urinary excretion in patients with chronic obstructive pulmonary disease. , 1994, Respiration; international review of thoracic diseases.

[29]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[30]  B. Battistini,et al.  Endothelins: circulating plasma levels and presence in other biologic fluids. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[31]  M. S. Singh,et al.  Development of a shuttle walking test of disability in patients with chronic airways obstruction. , 1992, Thorax.

[32]  P. Binkley,et al.  Plasma Endothelin Correlates With the Extent of Pulmonary Hypertension in Patients With Chronic Congestive Heart Failure , 1992, Circulation.

[33]  J. Ghali,et al.  Elevated pulmonary artery pressure. An independent predictor of mortality. , 1991, Chest.

[34]  J. Ketelslegers,et al.  ENDOTHELIN IN URINE , 1989, The Lancet.

[35]  P. Jones,et al.  A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. , 1989, Clinical science.

[36]  A. Van Tosh,et al.  Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. , 1985, Journal of the American College of Cardiology.

[37]  P. Fu,et al.  Enzymatic determination of total serum cholesterol. , 1974, Clinical chemistry.